Hormone Therapy (HT) remains the most effective option to treat menopausal symptoms. There are many good clinical data to indicate that the use of HT started in early menopause is effective and safe. The Asia-Pacific Hormone Replacement Therapy Market is estimated at USD 2.21 billion in 2018 and is predicted to reach USD 3.24 billion by 2023, growing at a CAGR of 7.92%.
Growing awareness on post-menopausal hazards, reimbursement policies, novel formulations, rise in unmet medical needs which require the employment of hormone therapy, benefits like lower risk of fractures are the few factors propelling the growth of Asia-Pacific hormone replacement therapy market.
The major factor acting as a hurdle for market growth in the Asia-Pacific region is the cost of therapy. Normally, the therapy costs around $ 10,000. This is a pretty high amount considering the economic conditions of people in most of the countries in the Asia-Pacific region. Further, the risk of side effects, such as bloating, mood changes, and nausea, bleeding, breast tenderness or enlargement, headaches, risk of breast cancer, heart disease, and stroke is restraining the growth of the Asia-Pacific market. Along with this, women with high susceptibility to coronary diseases are kept away from taking hormone replacement therapy.
The Asia Pacific hormone replacement therapy market is segmented on the basis of hormone type into Estrogen Replacement Therapy, Growth Hormone Replacement Therapy, Thyroid replacement therapy and others. The estrogen replacement therapy segment dominates the market, representing more than half of the market. While other therapies are still new in these regions and takes some time to get acquainted. Additionally, on the basis of route of administration the market is classified as oral, parenteral, transdermal and other routes. The oral route is regarded as one of the safest and most preferred routes of drug administration.
Further, on the basis of geography, the Asia-Pacific hormone replacement therapy market is analysed under regions namely, India, China, Australia, Japan and South Korea. Japan holds the major share of the Asia-Pacific hormone replacement therapy market while India & China are expected to register high growth rates during the forecast period.
Some of the key players operating in the Asia-Pacific hormone replacement market are F. Hoffmann-La Roche, Novartis, Pfizer, Abbott Laboratories, Mylan Laboratories, Novo Nordisk, Amgen, Merck & Co., Bayer, Eli Lily, Wyeth and Hisamitsu Pharmaceutical Co. Inc.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Hormone Type
5.1.1 Estrogen Replacement Therapy
5.1.2 Growth Hormone Replacement Therapy
5.1.3 Thyroid Replacement Therapy
5.2 By Route of Administration
6. Geographical Analysis
6.5 South Korea
7. Pipeline Product Analysis
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials
7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.
8.1 PESTLE analysis
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9.Market Leaders' Analysis
9.1 Abbott Laboratories
9.1.2 Product Analysis
9.1.3 Financial analysis
9.1.4 Recent Developments
9.1.5 SWOT analysis
9.1.6 Analyst View
9.4 Mylan Laboratories
9.6 Merck & Co.
9.8 Eli Lily & Company
9.9 Novo Nordisk
9.11 F. Hoffmann-La Roche
9.12 Hisamitsu Pharmaceutical Co. Inc.
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11.1 Market Outlook
11.2 Investment Opportunities
a) List of Tables
b) List of Figures